Auxano Advisors LLC Makes New $719,000 Investment in Enovis Co. (NYSE:ENOV)

Auxano Advisors LLC bought a new position in Enovis Co. (NYSE:ENOV) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 12,839 shares of the company’s stock, valued at approximately $719,000.

Several other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Enovis by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,897,449 shares of the company’s stock worth $258,242,000 after purchasing an additional 51,319 shares during the period. Diamond Hill Capital Management Inc. raised its position in Enovis by 9.9% during the third quarter. Diamond Hill Capital Management Inc. now owns 2,429,173 shares of the company’s stock valued at $128,090,000 after buying an additional 219,659 shares during the period. DAVENPORT & Co LLC boosted its holdings in shares of Enovis by 12.6% during the fourth quarter. DAVENPORT & Co LLC now owns 1,879,425 shares of the company’s stock worth $105,920,000 after purchasing an additional 210,358 shares during the period. Allspring Global Investments Holdings LLC grew its position in Enovis by 0.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,031,710 shares of the company’s stock valued at $57,796,000 after purchasing an additional 4,274 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Enovis by 0.8% during the 3rd quarter. Principal Financial Group Inc. now owns 832,415 shares of the company’s stock valued at $43,893,000 after buying an additional 6,353 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ENOV has been the subject of several analyst reports. UBS Group started coverage on Enovis in a research report on Monday, January 22nd. They set a “buy” rating and a $75.00 target price for the company. William Blair began coverage on shares of Enovis in a research note on Wednesday, January 3rd. They issued an “outperform” rating on the stock. Wells Fargo & Company boosted their target price on shares of Enovis from $73.00 to $79.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Canaccord Genuity Group raised their price target on Enovis from $73.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Finally, Stephens began coverage on Enovis in a research report on Tuesday, February 13th. They set an “overweight” rating and a $72.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $75.43.

Enovis Price Performance

ENOV stock traded down $0.67 during midday trading on Tuesday, hitting $55.23. The stock had a trading volume of 447,880 shares, compared to its average volume of 454,209. Enovis Co. has a 52 week low of $43.04 and a 52 week high of $66.14. The company has a quick ratio of 1.16, a current ratio of 2.43 and a debt-to-equity ratio of 0.14. The stock has a 50-day simple moving average of $59.80 and a 200 day simple moving average of $55.65.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, February 22nd. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.76 by $0.03. Enovis had a positive return on equity of 3.84% and a negative net margin of 1.95%. The business had revenue of $455.00 million during the quarter, compared to the consensus estimate of $444.34 million. During the same quarter last year, the company earned $0.72 EPS. Enovis’s revenue was up 11.2% on a year-over-year basis. On average, analysts expect that Enovis Co. will post 2.58 earnings per share for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.